FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PLCD4-VIL1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PLCD4-VIL1
FusionPDB ID: 66008
FusionGDB2.0 ID: 66008
HgeneTgene
Gene symbol

PLCD4

VIL1

Gene ID

84812

7429

Gene namephospholipase C delta 4villin 1
Synonyms-D2S1471|VIL
Cytomap

2q35

2q35

Type of geneprotein-codingprotein-coding
Description1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-4PLC delta4phosphoinositide phospholipase C-delta-4villin-1
Modification date2020032020200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000417849, ENST00000432688, 
ENST00000450993, 
ENST00000440053, 
ENST00000248444, ENST00000392114, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 3 X 2=183 X 4 X 3=36
# samples 44
** MAII scorelog2(4/18*10)=1.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
log2(4/36*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: PLCD4 [Title/Abstract] AND VIL1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PLCD4 [Title/Abstract] AND VIL1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PLCD4(219487601)-VIL1(219313946), # samples:3
Anticipated loss of major functional domain due to fusion event.PLCD4-VIL1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PLCD4-VIL1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PLCD4-VIL1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PLCD4-VIL1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneVIL1

GO:0007173

epidermal growth factor receptor signaling pathway

17229814

TgeneVIL1

GO:0008360

regulation of cell shape

16921170

TgeneVIL1

GO:0009617

response to bacterium

17182858

TgeneVIL1

GO:0010634

positive regulation of epithelial cell migration

17229814

TgeneVIL1

GO:0030041

actin filament polymerization

11500485

TgeneVIL1

GO:0030042

actin filament depolymerization

11500485

TgeneVIL1

GO:0030335

positive regulation of cell migration

16921170

TgeneVIL1

GO:0032233

positive regulation of actin filament bundle assembly

19808673

TgeneVIL1

GO:0051014

actin filament severing

16921170|17182858|19808673

TgeneVIL1

GO:0051125

regulation of actin nucleation

16921170|17182858|19808673

TgeneVIL1

GO:0051693

actin filament capping

16921170|17182858|19808673

TgeneVIL1

GO:0060327

cytoplasmic actin-based contraction involved in cell motility

15342783

TgeneVIL1

GO:0071364

cellular response to epidermal growth factor stimulus

17229814



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:219487601/chr2:219313946)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PLCD4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across VIL1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000450993PLCD4chr2219487601+ENST00000248444VIL1chr2219313946+518411112971127276
ENST00000450993PLCD4chr2219487601+ENST00000392114VIL1chr2219313946+141311112971127276
ENST00000417849PLCD4chr2219487601+ENST00000248444VIL1chr2219313946+5030957143973276
ENST00000417849PLCD4chr2219487601+ENST00000392114VIL1chr2219313946+1259957143973276
ENST00000432688PLCD4chr2219487601+ENST00000248444VIL1chr2219313946+508710142241030268
ENST00000432688PLCD4chr2219487601+ENST00000392114VIL1chr2219313946+131610142241030268
ENST00000450993PLCD4chr2219487601+ENST00000248444VIL1chr2219313945+518411112971127276
ENST00000450993PLCD4chr2219487601+ENST00000392114VIL1chr2219313945+141311112971127276
ENST00000417849PLCD4chr2219487601+ENST00000248444VIL1chr2219313945+5030957143973276
ENST00000417849PLCD4chr2219487601+ENST00000392114VIL1chr2219313945+1259957143973276
ENST00000432688PLCD4chr2219487601+ENST00000248444VIL1chr2219313945+508710142241030268
ENST00000432688PLCD4chr2219487601+ENST00000392114VIL1chr2219313945+131610142241030268

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000450993ENST00000248444PLCD4chr2219487601+VIL1chr2219313946+0.0011623340.99883765
ENST00000450993ENST00000392114PLCD4chr2219487601+VIL1chr2219313946+0.0076218990.9923781
ENST00000417849ENST00000248444PLCD4chr2219487601+VIL1chr2219313946+0.0010976180.9989023
ENST00000417849ENST00000392114PLCD4chr2219487601+VIL1chr2219313946+0.0043250560.9956749
ENST00000432688ENST00000248444PLCD4chr2219487601+VIL1chr2219313946+0.0012116870.9987883
ENST00000432688ENST00000392114PLCD4chr2219487601+VIL1chr2219313946+0.005006040.994994
ENST00000450993ENST00000248444PLCD4chr2219487601+VIL1chr2219313945+0.0011623340.99883765
ENST00000450993ENST00000392114PLCD4chr2219487601+VIL1chr2219313945+0.0076218990.9923781
ENST00000417849ENST00000248444PLCD4chr2219487601+VIL1chr2219313945+0.0010976180.9989023
ENST00000417849ENST00000392114PLCD4chr2219487601+VIL1chr2219313945+0.0043250560.9956749
ENST00000432688ENST00000248444PLCD4chr2219487601+VIL1chr2219313945+0.0012116870.9987883
ENST00000432688ENST00000392114PLCD4chr2219487601+VIL1chr2219313945+0.005006040.994994

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PLCD4-VIL1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide

Top

Potential FusionNeoAntigen Information of PLCD4-VIL1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Potential FusionNeoAntigen Information of PLCD4-VIL1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of PLCD4-VIL1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PLCD4-VIL1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score

Top

Vaccine Design for the FusionNeoAntigens of PLCD4-VIL1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of PLCD4-VIL1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample

Top

Potential target of CAR-T therapy development for PLCD4-VIL1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PLCD4-VIL1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PLCD4-VIL1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource